Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.75
- Piotroski Score 4.00
- Grade Buy
- Symbol (XLO)
- Company Xilio Therapeutics, Inc.
- Price $1.30
- Changes Percentage (-10.04%)
- Change -$0.15
- Day Low $1.25
- Day High $1.45
- Year High $2.14
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/08/2024
- Fiscal Year End N/A
- Average Stock Price Target $7.00
- High Stock Price Target $7.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.57
- Trailing P/E Ratio -0.41
- Forward P/E Ratio -0.41
- P/E Growth -0.41
- Net Income $-76,404,000
Income Statement
Quarterly
Annual
Latest News of XLO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Can Xilio Therapeutics (NASDAQ:XLO) Afford To Invest In Growth?
Shareholders can still profit from a money-losing business if they buy it at the right price. Analyzing Xilio Therapeutics' cash burn and runway, it's crucial for the company to reduce spending or rai...
By Yahoo! Finance | 4 months ago -
Pfizer lifts profit view on cost cuts, smaller drop in Paxlovid
By Bhanvi Satija and Sriparna Roy(Reuters) -Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, boosted by cost cutting efforts a...
By Reuters | 6 months ago -
Pfizer lifts profit view on cost cuts, smaller drop in Paxlovid demand
By Bhanvi Satija and Sriparna Roy(Reuters) -Pfizer lifted its annual profit forecast on Wednesday, and reported first-quarter results that topped Wall Street estimates on cost cuts, a smaller-than-fe...
By Reuters | 6 months ago
